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Plasmacytoid dendritic cells play important roles in inducing
immune tolerance, preventing allograft rejection, and
regulating immune responses in both autoimmune disease
and graft-versus-host disease. In order to evaluate a possible
protective effect of plasmacytoid dendritic cells against
renal inflammation and injury, we purified these cells from
mouse spleens and adoptively transferred lipopolysaccharide
(LPS)-treated cells, modified ex vivo, into mice with
adriamycin nephropathy. These LPS-treated cells localized
to the kidney cortex and the lymph nodes draining the
kidney, and protected the kidney from injury during
adriamycin nephropathy. Glomerulosclerosis, tubular
atrophy, interstitial expansion, proteinuria, and creatinine
clearance were significantly reduced in mice with adriamycin
nephropathy subsequently treated with LPS-activated
plasmacytoid dendritic cells as compared to the kidney injury
in mice given naive plasmacytoid dendritic cells. In addition,
LPS-pretreated cells, but not naive plasmacytoid dendritic
cells, convert CD4þCD25 T cells into Foxp3þ regulatory
T cells and suppress the proinflammatory cytokine
production of endogenous renal macrophages. This may
explain their ability to protect against renal injury in
adriamycin nephropathy.
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Plasmacytoid dendritic cells (pDCs) were identified in 1958 as
a cell type similar to plasma cells but lacking B cell and plasma
cell markers. These cells were found in the T-cell zones of
human lymphoid tissue.1 It has since been recognized that
these cells correspond to circulating immature CD11c
dendritic cells (DCs) that can be induced to develop DC
morphology.2 The murine equivalent of human pDCs are
CD11cþCD11bB220þGr-1þ cells that are present within
lymph nodes and spleen, and differ from myeloid dendritic
cells (mDCs) that are CD11bþB220. Besides these differences
in phenotypic markers, pDCs and mDCs also differ from each
other in terms of function. mDCs are professional antigen-
presenting cells involved in T-cell activation and initiation of
adaptive immune response, whereas pDCs are considered to
be poor antigen-presenting cells and T-cell stimulators based
on their low surface expression of major histocompatibility
complex and classical costimulatory molecules. However,
upon maturation with CD154 and Toll-like receptors (TLRs),
pDCs can become potent antigen-presenting cells and are
capable of stimulating T-cell proliferation and differentiation.3
DCs can be licensed to become regulatory by a variety
of cytokines including interleukin-10 (IL-10)/transforming
growth factor-b (TGF-b),4 vasoactive intestinal peptide,5 and
endogenous glycan-binding protein (galectin 1).6 pDCs are
able to induce either T helper (Th)1- or Th2-type immune
responses depending on the type of stimulation and the dose
of antigen.7 Upon viral infection, pDCs produce large
amounts of type I interferon and have therefore been
regarded as an important component of innate immunity.8
On the other hand, IL-3- and CD154-treated pDCs preferen-
tially prime Th2 cells, possibly through engagement of
costimulatory molecules such as OX40 ligand.9 pDCs can
also be modified into both inflammatory and regulatory
phenotypes by synthetic oligodeoxynucleotide containing
unmethylated cytosine–guanine (CpG), and have been shown
to induce allogeneic T-cell hyporesponsiveness and prolong
cardiac graft survival by increasing expression of IL-10,
TGF-b, and IL-6.10 Zwiorek et al.11 showed that CpG-
stimulated pDCs can exhibit proinflammatory effects via
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their expression of IL-1, tumor necrosis factor-a, and
interferon-g. In contrast, pDCs modulated by lipopoly-
saccharide (LPS) have been shown to be capable of
suppressing experimental autoimmune encephalomyelitis12
via enhanced secretion of anti-inflammatory cytokines
IL-10, TGF-b, and IL-13. Moreover human pDCs stimulated
with CpG oligodeoxynucleotide have been shown to play
important regulatory roles in autoimmune diseases and
graft-versus-host diseases.13–18 pDCs may also exert effects on
regulatory T cells (Tregs); a possible mediator of this effect
of pDCs on Tregs is indoleamine 2,3–dioxygenase (IDO).19,20
Whereas there is an increasing understanding of pDCs, their
role in chronic renal disease remains poorly defined.
Adriamycin nephropathy (AN) is a chronic kidney disease
model characterized by proteinuria, progressive glomerulo-
sclerosis, and tubulointerstitial damage, and it mimics human
focal segmental glomerulosclerosis. Our previous studies have
shown that reconstitution of Tregs expressing high levels of
Foxp3 (forkhead box P3) in severe combined immunodeficient
(SCID) mice with AN reduced glomerulosclerosis and tubular
injury in comparison with control SCID mice with AN.21
Our studies have also shown that macrophages modulated by
IL-10/TGF-b or IL-13/4 are able to reduce renal injury in
murine AN.22,23 In this study, we sought to determine whether
or not adoptive transfer of splenic pDCs that were modified
ex vivo to a regulatory phenotype and infused into AN mice
could protect mice against progressive renal injury. Our results
showed that adoptive transfer of pDCs modulated with LPS
can in fact protect mice against AN, and suggested two novel
mechanisms of protection. An increase in Foxp3þ Tregs by
pDCs was observed and the induction of Tregs was found to
be IDO dependent. In addition, proinflammatory cytokine
production by endogenous renal macrophages was decreased
in mice treated with LPS-pretreated pDCs.
RESULTS
pDC phenotype and function
To characterize the phenotype of pDCs, the expression of the
B7-H family of molecules in naive pDCs and LPS-pretreated
pDCs was assessed. LPS-pretreated pDCs expressed higher levels
of B7-H1 but not B7-H2, B7-H3, or B7-H4 than did naive
pDCs (Figure 1; B7-H1 expression relative to b-actin, naive
pDCs vs. LPS-pretreated pDCs 1.5±0.3 vs. 13.2±2.7, Po0.01).
In addition, to determine the function of pDCs, the cytokine
expression of pDCs was assessed; there was stronger expression
of IL-10, TGF-b, and IDO but not IL-12 in LPS-pretreated
pDCs and CpG-pretreated pDCs compared with naive
pDCs (IDO mRNA expression relative to b-actin naive pDC
vs. LPS-pretreated pDC 1.8±0.4 vs. 7.2±1.6, Po0.01). Also,
the protein level of IL-10 and TGF-b of supernatant and cellular
IDO from cultured LPS-pretreated pDCs was much higher than
those from cultured naive pDCs (Po0.01; Figure 1d).
pDCs expressed TLR4 after LPS exposure
As TLR4 functions as a LPS-sensing receptor, we tested
TLR4 expression and found that TLR4 was expressed on
significantly more LPS-pretreated pDCs than naive pDCs
(0.6±0.1% vs. 18.2±2.7%, Po0.01; Figure 2).
Effect of pDCs on renal structural injury
At 4 weeks after adriamycin, we examined the effect of pDCs
on renal structural injury. In AN, renal injury is characterized
by glomerulosclerosis, tubular atrophy, interstitial volume
expansion, and interstitial fibrosis. Glomerulosclerosis was
significantly reduced in AN mice transfused with LPS-
pretreated pDCs compared with AN mice transfused with
naive pDCs and untransfused AN mice (Figure 3). Similarly,
tubulointerstitial injury was significantly improved in AN
mice transfused with LPS-pretreated pDCs compared with
mice transfused with naive pDC and untransfused AN mice
(Figure 3; normal vs. AN control vs. ANþ naive pDC vs.
ANþ LPS-pretreated pDC: glomerulosclerosis 2.3±0.3 vs.
28.0±4.6 vs. 28.4±3.7 vs. 12.6±1.8%, Po0.01, tubular cell
height 7.3±0.4 vs. 1.5±0.2 vs. 1.1±0.3 vs. 5.7±0.9 mm,
Po0.05, interstitial volume 1.8±0.6 vs. 26.8±1.1 vs. 28.3±
2.5 vs. 12.6±1.0%, Po0.01, interstitial fibrosis 2.3±0.6 vs.
20.1±0.5 vs. 18.9±1.4 vs. 12.3±1.0%, Po0.01). These
results indicate that LPS-pretreated pDCs protected against
renal injury in AN.
Effect of pDCs on renal function
To explore the effect of pDCs on renal function, serum
creatinine and urinary protein were measured in each group
at 4 weeks after adriamycin. In AN mice, serum creatinine
and urinary protein excretion were significantly increased
compared with normal mice, and were significantly improved
in AN mice transfused with LPS-pretreated pDCs compared
with untransfused AN mice or those transfused with naive
pDCs. Creatinine clearance was also improved after pDC
transfusion (normal vs. AN vs. ANþ naive pDC vs. ANþ
LPS-pretreated pDC: serum creatinine 5.1±0.5 vs. 16.5±2.3
vs. 18.7±3.8 vs. 11.5±1.4 mmol/l, Po0.05; urinary protein
50.7±26.3 vs. 403.5±104.3 vs. 458.8±49.2 vs. 134.5±
23.6 mg/12 h, Po0.01; creatinine clearance 34.0±4.1 vs.
14.6±1.5 vs. 15.1±2.6 vs. 24.5±3.0 ml/min, Po0.05; urine
protein/urine creatinine ratio 20.8±2.6 vs. 938.4±98.4 vs.
1068.5±123.4 vs. 551.1±76.2 mg/mmol, Po0.01; Figure 3).
Leukocyte infiltration
In AN, focal segmental glomerulosclerosis is accompanied by
interstitial inflammation. Therefore, renal leukocyte infiltra-
tion at week 4 after adriamycin was examined using anti-
F4/80, -CD4, and -CD8 antibodies. The numbers of
macrophages, CD4þ T cells, and CD8þ T cells were
increased in all AN mice. However, the numbers of these
cells were markedly reduced in AN mice transfused with
LPS-pretreated pDCs compared with untransfused AN mice
and AN mice transfused with naive pDCs (Figure 4).
pDC tracking in lymph nodes and kidneys
To determine whether a difference in access to organs of
interest explained the effects of LPS-pretreated vs. naive
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pDCs, tracking studies were performed. At day 28, fluores-
cently labeled cells were seen in kidney, kidney-draining
lymph nodes (KDLNs), and spleen of AN mice transfused
with LPS-pretreated pDCs and naive pDCs. Both DiI-stained
LPS-pretreated pDCs and naive pDCs were located mostly in
kidney interstitium and in paracortex of KDLNs in similar
numbers (Figure 5). Thus, the protective effect of LPS-
pretreated pDCs vs. naive pDCs was not explained by a
difference in access.
Induction of Tregs
To further explore the mechanism by which LPS-pretreated
pDCs was protective in AN, the number of Foxp3þ CD4þ
cells was examined and found to be significantly increased in
KDLNs and kidney of AN mice transfused with LPS-pretreated
pDCs compared with those treated with naive pDCs or
untransfused AN mice (naive pDCs vs. LPS-pretreated pDCs
in KDLNs 6.67±0.8% vs. 18.69±2.5%, Po0.01; Figure 6a
and b). In vitro, LPS-pretreated pDCs significantly increased
the percentage of Foxp3þ T cells when cocultured with
CD4þCD25 T cells for 7 days, whereas naive pDCs had no
effect. This effect was found to be contact dependent in
Transwell experiments (Figure 6c and d). The blockade of
IDO expression on modified DCs with 1-methyl-D-tryptophan
(D-1MT) eliminated induction of Foxp3þ T cells by LPS-
pretreated pDCs, whereas blockade with antibodies against
IL-10, TGF-b, or B7-H1 had no effect (Figure 6e). This
suggested that at least part of the protective effect of LPS-
pretreated pDCs in AN could be due to induction of Tregs in
KDLNs and kidney in an IDO-dependent manner.
Deactivation of effector macrophages in vitro and
macrophage phenotype in vivo
In addition to induction of Foxp3þ Tregs, we explored other
potential protective mechanisms by examining the interac-
tion of pDCs with macrophages both in vitro and in vivo.
LPS-pretreated pDCs suppressed proinflammatory cytokine
production of effector macrophages (M1) in vitro and in vivo
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Figure 1 |Phenotypic features of plasmacytoid dendritic cells (pDCs). (a, b) The expression of B7-H1, B7-H2, B7-H3, and B7-H4 on
naive pDCs and lipopolysaccharide (LPS)-pretreated pDCs was examined by (a) fluorescence-activated cell sorting (FACS) and (b) real-time
PCR. (c) The mRNA expression of interleukin-10 (IL-10), transforming growth factor-b (TGF-b), indoleamine 2,3–dioxygenase (IDO), and IL-12
by naive pDCs, LPS-pretreated pDCs, and cytosine–guanine (CpG)-pretreated pDCs was examined by real-time PCR. (d) The protein level of
IL-10, TGF-b, IDO, and IL-12 secreted by naive pDCs and LPS-pretreated pDCs was examined by enzyme-linked immunosorbent assay
(ELISA). Data represent the mean±s.d. of three experiments. *Po0.05 and **Po0.01 vs. counterparts from other groups.
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as shown by suppression of mRNA expression of pro-
inflammatory cytokines tumor necrosis factor-a, IL-12, and
inducible nitric oxide synthase, whereas naive pDCs had no
effect. However, there were no differences in the expression of
markers of protective macrophage (M2) mannose receptor,
arginase, IL-10, and TGF-b on M1 cocultured with naive
pDCs versus LPS-pretreated pDCs (Figure 7a). Endogenous
macrophages isolated from kidneys of each of the four groups
were examined. Similar to the in vitro studies, the mRNA
expression of tumor necrosis factor-a, IL-12, and inducible
nitric oxide synthase of endogenous kidney macrophages was
reduced significantly in AN mice receiving LPS-pretreated
pDCs, but not naive pDCs, and there was no change in
expression of M2 macrophages markers (Figure 7b).
Together, these data suggested a further mechanism by which
LPS-pretreated pDCs could prevent renal injury, that is, by
deactivation of host macrophages.
DISCUSSION
In this study, the effects of splenic pDCs were examined in
murine AN. We demonstrated that splenic pDCs are able to
reduce renal structural and functional injury and monocyte
infiltration in AN. The mechanisms by which pDCs protected
against renal injury appeared to involve their ability to
convert CD4þCD25 T cells into CD4þCD25þ Foxp3þ
Tregs in KDLNs and kidney via increasing the expression of
IDO and to suppress proinflammatory cytokine production
of endogenous renal macrophages.
DCs largely reside in renal tubulointerstitium, forming
an intricate immune sentinel network.24 A quantitative
evaluation of DC subsets has shown that both mDCs and
pDCs participate in inflammatory renal injury,25 suggesting
that both mDCs and pDCs play a role in tubulointerstitial
injury under pathophysiological conditions. In addition, a
significant number of pDCs have been found at sites of
inflammation in lupus nephritis. Inhibition of interferon-a
produced by pDCs with a specific TLR7 inhibitor IRS954
has been shown to ameliorate disease progression in lupus-
prone mice.26 Moreover, Coates et al.27 demonstrated that
Fms-like tyrosine kinase 3 ligand increased the number of
CD11cþCD45RAþ pDCs in glomeruli and interstitium of
kidneys and that these pDCs were functionally immature and
exhibited suppressive features. In general, pDCs play crucial
roles in the development and resolution of renal inflamma-
tion. DCs are able to induce dynamic alterations in their
function and phenotype to induce or suppress immune
responses.28 For example, depletion of renal DCs enhanced
renal injury in nephrotoxic nephritis29,30 and impaired
recovery from ischemia/reperfusion injury,31 indicating a
protective role of DCs. However, depletion of renal activated
DCs rapidly resolved established renal immunopathology in
a mouse model of glomerular injury, suggesting a facilitatory
role for DCs in the progression of renal diseases.32 In the
study of nephrotoxic nephritis, all DCs were depleted at an
early point of disease and therefore the resident DCs were
also removed.30 It is possible that depletion of only these
resident DCs was responsible for the worse renal injury. Thus,
the effect of DCs in kidney may depend on the particular
type of renal disease (for example, immune vs. nonimmune)
or the functional state of renal DCs (for example, activated or
resting; mature or immature). An alternative way to clarify
the role of DCs in renal disease is the use of adoptive transfer.
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We adoptively transferred unstimulated (naive) and pDCs
stimulated with LPS into AN mice, and showed protective
effects with stimulated but not naive pDCs.
pDCs modified by CpG have been shown to induce allo-
geneic T-cell hyporesponsiveness and prolong cardiac graft
survival.10 Furthermore, pDCs modified by LPS have also
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been shown to be capable of suppressing experimental
autoimmune encephalomyelitis.12 In this study, we examined
the suppressive capacity of both LPS-pretreated and naive
pDCs. pDCs pretreated with LPS showed high expression
of B7-H1, IDO, and the anti-inflammatory cytokines IL-10
and TGF-b. Both CpG- and LPS-pretreated pDCs expressed
high levels of B7-H1. B7-H1 has been shown to down-
regulate T-cell activation.33,34 Increasing B7-H1 expression
in pDCs has been shown to induce allogeneic T-cell
hyporesponsiveness and prolong graft survival.10 pDCs
also express high levels of IDO after LPS or CpG stimulation.
IDO is a component of the enzymatic pathway involved
in the catabolism of tryptophan. Tryptophan depletion has
been shown to suppress proliferation of activated T cells.35,36
The role of IDO in regulatory function of pDCs has
been addressed previously.37 CpG oligodeoxynucleotide
activation of pDCs significantly increased their expres-
sion of IDO and resulted in the generation of inducible
Tregs from CD4þCD25 T cells.38 In this study, we found
that LPS-modulated pDCs also expressed high levels
of IDO.
It has been shown that pDC were able to suppress auto-
immune encephalomyelitis following their exposure to LPS,12
and to induce tolerance in experimental models of asthma,
and in allogeneic hematopoietic stem cell, heart, and liver
transplantation.10,39–41 However, whether pDCs can be used
to treat chronic kidney disease is unknown. This study, for
first time, showed that LPS-pretreated pDCs can reduce
glomerulosclerosis, tubulointerstitial injury, and interstitial
fibrosis, and improve renal function in a model of chronic
proteinuric renal disease. pDCs, both naive and pretreated
with LPS, were able to reach the site of injury within kidneys,
and to migrate to KDLNs. However, pDCs modified with LPS
ex vivo into a regulatory phenotype, but not unstimulated
pDCs, could ameliorate renal injury and reduce renal infil-
tration with inflammatory cells. Thus, it is their phenotype
and not access to sites of inflammation that distinguishes
LPS-pretreated pDCs from naive pDCs, and determines their
protective effect.
In this study, LPS-pretreated pDCs showed inhibitory
functions, yet the mechanism underlying pDC modulation
by LPS into a regulatory phenotype is unknown. We found
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that some pDCs after LPS treatment had increased expression
of the LPS receptor TLR4, consistent with its involvement in
the effect of LPS on pDCs. This result is in line with that of
others investigators who showed that TLR4 was significantly
increased after LPS in murine liver and thymic pDCs.42,43
However, in our study and similar to that of others, only
18% of pDCs expressed TLR4, suggesting that the effects of
LPS might be mediated by other unknown pathways not
involving TLR4. It has been reported that pDCs can be
induced to express IDO under inflammatory conditions in
humans and mice;44 however, how LPS induces IDO is not
clear.
This study explored several potential mechanisms by
which adoptive transfer of LPS-pretreated pDCs might
reduce renal injury. First, we examined an effect on
macrophages. LPS-pretreated pDCs suppressed endogenous
macrophages by reducing their expression of inducible nitric
oxide synthase and inflammatory cytokines. Inducible nitric
oxide synthase, tumor necrosis factor-a, and IL-12 from
macrophages have been demonstrated to be important
mediators of renal inflammation and fibrosis in many types
of chronic kidney disease.45–47 Endogenous renal macro-
phages suppressed by LPS-pretreated pDCs secreted less
proinflammatory cytokines that in turn could have reduced
accumulation of T cells and macrophages. In this study we
did not find any evidence that LPS-pretreated pDCs were able
to convert M1 macrophages in vitro or effector macrophages
in vivo to alternatively activated or protective macrophages
(M2). Next, we examined an effect on Tregs. Interestingly,
Treg numbers were significantly increased in KDLNs and
kidneys after adoptive transfer of LPS-pretreated pDCs.
Moreover, in vitro, LPS-pretreated pDCs were able to convert
CD4þCD25 T cells into Foxp3þ Tregs. When IDO was
blocked, LPS-pretreated pDCs did not increase the number
of Foxp3þ Tregs, suggesting that the effects of pDCs on
T cells are IDO dependent. This result recalls previous studies
in which human pDCs activated by human immuno-
deficiency virus induced Tregs through an IDO-dependent
mechanism.48,49
In conclusion, we have demonstrated that LPS-pretreated
pDCs can protect against renal functional and histological
injury in mice with AN. The mechanisms underlying the
protective effects of LPS-pretreated pDCs may involve their
IDO-dependent ability to transform naive T cells into Tregs
in kidney and lymph nodes and to suppress proinflammatory
cytokine production of macrophages. The regulatory ability
of pDCs may provide a novel and effective therapeutic
approach for chronic kidney disease.
MATERIALS AND METHODS
Murine AN model
Male BALB/c mice, 6 to 8 weeks old, obtained from the
Animal Resources Centre (Perth, Australia) were used in this study.
The Animal Ethics Committee of Westmead Hospital approved
all procedures. Adriamycin (9.8mg/kg) was injected once via the
tail vein of each non-anesthetized BALB/c mouse 5 days before
pDCs were transfused into mice. Mice were divided into four
groups (n¼ 7 per group); normal, AN control, ANþ naive pDC,
and ANþ LPS-pretreated pDCs. Mice were killed on day 28 after
adriamycin administration. Kidney, KDLNs, and spleens were
examined.
pDC isolation and activation
pDCs were purified from spleen using anti-mPDCA-1 microbeads
(from Miltenyi Biotec, Teterrow, Germany). A total of 92.3% of separated
cells were CD11cþB220þ (pDC marker), 0.4% CD11cþB220
(bone marrow DC marker); 0.07% CD49bþ (natural killer cell
marker); 0.2% CD19þ (B-cell marker); 2.4% CD11bþ (macro-
phage marker); and 7.6% CD4þ (T-cell marker). pDCs were
stimulated with LPS (0.5 mg/ml, Sigma) for 24 h to become LPS-
pretreated pDCs.
Quantitative reverse transcription–PCR
RNA was isolated and reverse-transcribed with cDNA synthesis kit
(Invitrogen, Carlsbad, CA), and real-time PCR using the SYBR
(Invitrogen). The analysis method has been described previously.50
The PCR primer sequences are presented in Table 1.
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Enzyme-linked immunosorbent assay (ELISA)
IL-12, TGF-b, and IL-10 protein levels were measured in culture
supernatants using IL-12, TGF-b, and IL-10 ELISA kits (R&D
Systems, Minneapoils, MN), and for IDO measurement, the cellular
extracts were obtained by lysis of 1 105 pDCs in lysis buffer and
assessed with IDO ELISA kit (antibodies-online GmbH, Atlanta,
GA) according to the manufacturer’s instructions.
Flow cytometry analysis
Naive pDCs were suspended in fluorescence-activated cell sorter
wash buffer (phosphate-buffered saline) and CD32/16 Fc block
(eBiosciences, San Diego, CA). To analyze purity of naive pDCs, cells
were stained with fluorescein isothiocyanate–conjugated anti-mouse
B220 (Miltenyi Biotec, Bergisch Gladbach, Germany), CD49b
(Biolegend, San Diego, CA), CD4 (BD Biosciences, San Jose, CA),
CD8 (eBiosciences), and phycoerythrin-conjugated anti-mouse
CD11c (eBiosciences) and CD11b (eBiosciences). To analyze pDC
surface antigen expression, phycoerythrin-conjugated anti-mouse
B7-H1, B7-H2, B7-H3, and B7-H4 (all from eBiosciences) were
used. For intracellular staining of Foxp3, T cells were fixed and
stained with phycoerythrin-Cy5-conjugated anti-mouse Foxp3
(eBiosciences). Armenian hamster IgG was used as control antibody
for CD11c; rat IgG2a for the antibodies to CD19, B7-H1, B7-H2, and
Foxp3; and rat IgG2b for antibodies to CD11b, B7-H3, and B7-H4.
Flow cytometry was performed using a fluorescence-activated cell
sorter Calibur cytometer (BD Biosciences). Percentage of positive cells
was analyzed using Cellquest software and FlowJo (Tree Star, Ashland,
OR) in comparison with fluorescence-labeled isotype controls.
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Coculture experiments
For Foxp3þ Treg induction experiments, CD4þCD25 T cells
were cocultured with freshly isolated naive pDCs or LPS-pretreated
pDCs for 7 days. For transwell experiments, CD4þCD25 T cells
and LPS-pretreated pDCs were cocultured in 24-well plates and
placed separately in transwell chambers (0.4 mm, Millipore, Kilsy,
VIC, Australia). For neutralizing antibody blocking, CD4þCD25
T cells and LPS-pretreated pDCs were cocultured in 24-well plates in
the presence of IL-10-, TGF-b-, and B7-H1-neutralizing antibodies
(10mg/ml each) for 7 days. D-1MT (Sigma-Aldrich, St Louis, MO)
was prepared as a 20mmol/l stock solution in 0.1 M NaOH, adjusted
to pH 7.4, and stored at 20 1C protected from light. For in vitro
use, D-1MT was added in a final concentration of 100mM into
coculture medium. After incubation, CD4þ T cells were stained with
Foxp3 antibody and analyzed by fluorescence-activated cell sorting.
Splenic macrophages were separated by CD11b microbeads (Mitenyi
Biotech, Bergisch Gladbach, Germany) and were grown on the bottom
of a 24-well plate with LPS for 2 h to become effector macrophages
(M1). pDCs were added onto the same plate and cocultured
with M1 for 24 h. After incubation, expression of markers of effector
(M1) and protective (M2) macrophages were examined.
pDC DiI labeling and adoptive transfer to BALB/c mice
Naive pDC and LPS-pretreated pDCs were labeled with DiI
(Invitrogen).51 One million cells were transferred into AN-treated
mice by a single tail vein injection at day 5 after adriamycin
administration.
Renal function
All urine and blood samples were prepared and examined by the
Institute of Clinical Pathology and Medical Research (Westmead
Hospital, Sydney, Australia).
Histology
Coronal sections of renal tissue were immersion-fixed in 10%
neutral buffered formalin and embedded in paraffin. Sections 5 mm
thick were stained with periodic acid–Schiff or trichrome. To
quantitate tubular atrophy, the tubule cell height of individual
cortical tubules was measured using line morphometry (magnifica-
tion  200) by computer image analysis software (ImageJ, Rockville,
MD).52 The tubular diameter was defined as the length of a straight
line that passed through the center of a symmetrically sectioned
tubule and joining two points on the tubular circumference. A total
of 50 randomly selected cortical tubules in 10 nonoverlapping fields
(magnification  200) were measured, and the mean cross-sectional
tubule cell height was determined for each section. The cortical
interstitial volume included the tubular basement membrane and
peritubular capillaries. To quantitate this area, cortical fields
(magnification  200) were viewed on a video screen, and the area
of interstitial space was determined with image analysis software and
was expressed as a percentage of the total area of the field. The mean
percentage area of five non-overlapping cortical fields was calculated
for each section. Interstitial fibrosis was assessed and quantified on
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Figure 7 | Lipopolysaccharide (LPS)-pretreated plasmacytoid
dendritic cell (pDC) suppression of effector macrophages (M1)
in vitro and in vivo. (a) M1 were cocultured with pDCs in vitro for
24 h. The mRNA expression of tumor necrosis factor-a (TNF-a),
interleukin-12 (IL-12), inducible nitric oxide synthase (iNOS),
mannose receptor, arginase, IL-10, and transforming growth
factor-b (TGF-b) of M1 was examined by real-time PCR. **Po0.01
vs. M1 and M1þ naive pDCs. (b) Endogenous macrophages (EMs)
were isolated from kidney of each of the four groups. The mRNA
expression of TNF-a, IL-12, iNOS, mannose receptor, arginase,
IL-10, and TGF-b of macrophages was examined by real-time PCR.
AN, adriamycin nephropathy. **Po0.01 vs. M1 and M1þ naive
pDCs.
Table 1 | Real-time PCR primers
Gene Primer sequence (50–30) Product
IL-10 (F) CCAGTACAGCCGGGAAGACA 121
IL-10 (R) CAGCTGGTCCTTTGTTTGAAAGA
TGF-b (F) TTAGGAAGGACCTGGGTTGGA 121
TGF-b (R) AGGGCAAGGACCTTGCTGTA
TNF-a (F) GCTGAGCTCAAACCCTGGTA 118
TNF-a (R) CGGACTCCGCAAAGTCTAAG
iNOS (F) CACCTTGGAGTTCACCCAGT 170
iNOS (R) ACCACTCGTACTTGGGATGC
IDO (F) AAGGGCTTCTTCCTCGTCTC 200
IDO (R) AAAAACGTGTCTGGGTCCAC
IL-12 (F) ACGGCCAGAGAAAAACTGAA 218
IL-12 (R) CTACCAAGGCACAGGGTCAT
IFN-a (F) CTACTGGCCAACCTGCTCTC 258
IFN-a (R) TTCCATGCAGCAGATGAGTC
Abbreviations: F, forward; IDO, indoleamine 2,3–dioxygenase; IFN-a, interferon-a;
IL-10, interleukin-10; iNOS, inducible nitric oxide synthase; R, reverse; TGF-b,
transforming growth factor-b; TNF-a, tumor necrosis factor-a.
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trichrome-stained sections by point counting using ImageJ software
in each of 10 non-overlapping randomly selected cortical fields.
Points falling within blue areas (fibrosis) were considered as positive.
Scores derived from 10 fields per kidney section (3 sections/per
mouse) were collected for the analyses.
Immunohistochemistry
For immunohistochemical staining of macrophages, CD4þ , and
CD8þ cells, rat anti-mouse F4/80, CD4, and CD8 antibodies (BD
Pharmingen, Franklin Lakes, NJ) were used as the primary
antibodies. Biotinylated peroxidase (ZYMED, South San Francisco, CA)
and Streptavidin (ZYMED) were used for the secondary antibodies.
Kidney sections were placed in optimal cutting temperature com-
pound (Sakura Fintek, Torrance, CA). Sections of 5 mm were cut,
dried overnight, and fixed in cold acetone for 8min. Endogenous
peroxidase activity was blocked by 0.3% (v/v) H2O2 solution for
15min when incubating the slides. Biotin Blocking System (Dako,
Carpinteria, CA) was used to block endogenous avidin-binding
activity. Normal rat immunoglobulin was used for control sections.
Sections were incubated with biotinylated polyclonal rabbit anti-rat
immunoglobulin (Dako Corporation, Glostrup, Denmark) or RTU
Vectastain Elite ABC Peroxidase Kit (Vector Laboratories, Burlin-
game, CA), and 3,3–diaminobenzidine substratechromogen solution
(Dako) was applied and then washed. Slides were counterstained
with hematoxylin (Sigma-Aldrich, Steinheim, Germany). For
assessment of interstitial inflammation, positively stained cells
located in the interstitial area were counted from more than 20
random cortical fields (magnification  200) in each section, and
the numbers averaged for each section.
Statistics
Renal functional data were log-transformed before analysis to
stabilize the variance. Statistical tests included unpaired two-tailed
Student’s test using one-way analysis of variance with Tukey’s
multiple comparison test. Statistical analyses were done using Prism
(Version 4, Graphpad, La Jolla, CA). Results are expressed as the
mean±s.d. A P-value ofo0.05 was considered statistically significant.
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